Skip to main content
Equibles
HUMA logo

HUMA · Humacyte, Inc. · Metrics

Track HUMA — free

Use HUMA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research HUMA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.44 +0.02 (+5.40%) At close · Oct 23
Rebalance outlook locked
Going-concern doubt — flagged Aug 12, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company will not have sufficient liquidity to fund its operations beyond one year from the issuance of these condensed consolidated financial statements if the Company is unable to generate sufficient cash flows from commercial sales on a timely basis and/or obtain additional capital. These factors raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 12, 2026
Market Cap
$120.95M
Shares
277.80M
Volume · Oct 23 2.61M Avg daily vol (3M) 6.43M

HUMA metrics

76 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.44
Market cap
$120.95M

Price action

20 metrics
Price change (1W)
+1.5%
Price change (30D)
-23.4%
Price change (3M)
-30.3%
Price change (6M)
-37.8%
Price change (YTD)
-54.7%
Price change (1Y)
-74.2%
Trailing year
Price change (5Y)
-95.5%
52-week high
$1.71
52-week low
$0.35
Change from 52-week high
-74.5%
Change from 52-week low
+23.0%
Annualized volatility
108.0%
Annualized volatility (3M)
103.5%
Beta
2.9
RSI (14D)
43.1
Price vs SMA 50
-19.8%
Price vs SMA 200
-47.2%
Avg volume (3M)
6.43M
Relative volume
0.4
Average dollar volume
$3.61M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
277.80M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
33.6×
reciprocal yield 3.0%
EV / EBITDA
—
EV / EBIT
—
P / sales
54.1×
reciprocal yield 1.8%
P / book
3.7
reciprocal yield 27.2%
FCF yield
-85.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-84.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-12

Profitability

9 metrics
Gross margin
-494.6%
Operating margin
-5,240.8%
Trailing 12 months
Net margin
-4,560.8%
Gross profit (TTM)
−$10.49M
Operating profit (TTM)
−$111.16M
Net income (TTM)
−$96.73M
Trailing 12 months
Diluted EPS (TTM)
$-0.55
FCF margin
-4,599.7%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.02

Growth

11 metrics
Revenue growth YoY
+34.9%
Year over year
Net income growth YoY
—
Revenue (TTM)
$2.12M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+50.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-309.4%
Return on assets
-70.1%
Debt / equity
1.2
Current ratio
6.2
EBITDA (TTM)
—
Free cash flow (TTM)
−$97.56M
Quick ratio
5.7
Interest coverage
-10.8
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$43.58M
Latest balance sheet
Cash & equivalents
$79.90M
Total assets
$138.09M
Total debt
$36.32M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$97.19M
Capital expenditures (TTM)
$367,000
R&D (TTM)
$69.48M
SG&A (TTM)
—
Stock compensation (TTM)
$10.71M
R&D / revenue
3,276.0%
Stock compensation / revenue
504.9%

Ownership (13F)

9 metrics
13F filers
173
13F filer change QoQ
+8
Institutional ownership
27.5%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
13.5%
Private-fund adviser ownership
12.3%
Active holders' share change QoQ
+83.6%
Holder tenure
6.5
Price vs estimated holder cost
-57.5%

Ownership (registered funds)

1 metrics
Index-fund ownership
6.6%

Short interest

3 metrics
Short interest
10.6%
Latest settlement · 7.3 days to cover
Days to cover
7.3d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
$30,370
Insider-sentiment score
77 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1818382 CUSIP 44486Q103 13F (30d) 24 filings 24 filers Visit website Investor relations